Eli Lilly and Company shares fell -1.9% this afternoon to a price of $454.25. The stock is still trading within range of its average target price of $456.1, and over the last 52 weeks, it has recorded a 4016.7% performance. Analysts have given the large-cap Pharmaceutical stock target prices ranging from $300.0 to $550.0 dollars per share, with an average rating of buy.
The stock has a very low short interest at 0.7%, and a short ratio of 2.16. The company's insiders own 0.15% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 84.0% of Eli Lilly and Company's shares being owned by this investor type.
Institutions Invested in Eli Lilly and Company
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-03-31 | Lilly Endowment, Inc | 11% | 102,543,810 | $46,580,525,692 |
| 2023-03-31 | Vanguard Group, Inc. (The) | 7% | 69,988,183 | $31,792,132,127 |
| 2023-03-31 | Blackrock Inc. | 7% | 65,571,525 | $29,785,865,231 |
| 2023-03-31 | PNC Financial Services Group, Inc. | 5% | 51,921,940 | $23,585,541,245 |
| 2023-03-31 | State Street Corporation | 4% | 33,236,143 | $15,097,517,957 |
| 2023-03-31 | FMR, LLC | 3% | 32,007,276 | $14,539,305,123 |
| 2023-03-31 | Capital World Investors | 3% | 27,588,540 | $12,532,094,295 |
| 2023-03-31 | Primecap Management Company | 3% | 25,367,550 | $11,523,209,587 |
| 2023-03-31 | Price (T.Rowe) Associates Inc | 2% | 22,722,734 | $10,321,801,919 |
| 2023-03-31 | Wellington Management Group, LLP | 2% | 20,324,267 | $9,232,298,284 |
Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on Eli Lilly and Company.
